Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£6.66M
Enterprise Value19.61M
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Fee-for-service Contract Research ModelA project-based fee-for-service model tied to pharma/biotech R&D creates predictable, repeatable revenue streams from specialized lab work. Over months this supports durable demand as drug discovery outsources complex proteomics, enabling steady utilization of lab capacity when demand is stable.
Specialized Proteomics Capabilities And IPDeep mass-spectrometry expertise and past development of proprietary reagents/software constitute structural competitive advantages. These technical barriers favor long-term client relationships for complex assays, higher switching costs for customers, and the ability to command premium pricing for specialized services.
Improving Cash Flow Trend In 2025Near-term improvement in operating and free cash flow signals progress toward stabilizing cash generation. If management sustains cost control and utilization, the reduced cash burn provides more runway for operations and reduces immediate refinancing pressure versus prior volatile years.
Bears Say
Declining Revenue And Margin DeteriorationFalling revenue combined with negative gross profit indicates structural margin pressure from pricing, mix, or cost base that impairs scalability. Persistent operating losses reduce reinvestment ability and make profitability recovery harder without sustained revenue growth or material cost restructuring.
High Leverage And Negative EquityDebt materially exceeding assets and a negative equity position create structural solvency and refinancing risks. This reduces financial flexibility for R&D, capex, or working capital, and raises the probability of dilution or costly funding solutions if cash generation does not improve.
Sustained Revenue Contraction TrendA multi-year decline in revenue undermines scale economics for a lab-intensive business, worsening fixed-cost absorption and competitiveness. Continued top-line contraction over months reduces bargaining power with suppliers and clients, and increases reliance on external funding to bridge the gap.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £6.66M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Jul 23, 2026 which is in 2 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.